Evolent Health (EVH) – Investment Analysts’ Recent Ratings Changes

Evolent Health (NYSE: EVH) has recently received a number of price target changes and ratings updates:

• 2/21/2025 – Evolent Health had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, down previously from $17.00.
• 2/21/2025 – Evolent Health had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
• 2/14/2025 – Evolent Health had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
• 2/12/2025 – Evolent Health had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
• 1/28/2025 – Evolent Health had its price target lowered by analysts at JPMorgan Chase & Co. from $15.00 to $13.00. They now have an “overweight” rating on the stock.
• 1/24/2025 – Evolent Health had its price target lowered by analysts at Oppenheimer Holdings Inc. from $28.00 to $18.00. They now have an “outperform” rating on the stock.
• 1/23/2025 – Evolent Health had its price target lowered by analysts at Canaccord Genuity Group Inc. from $23.00 to $16.00. They now have a “buy” rating on the stock.
• 1/22/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $20.00 to $15.00. They now have a “buy” rating on the stock.
• 1/21/2025 – Evolent Health had its price target lowered by analysts at Stephens from $16.00 to $12.00. They now have an “equal weight” rating on the stock.
• 1/16/2025 – Evolent Health had its price target lowered by analysts at UBS Group AG from $27.00 to $14.00. They now have a “buy” rating on the stock.
• 1/14/2025 – Evolent Health had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an “outperform” rating on the stock.
• 1/13/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at JMP Securities from $27.00 to $18.00. They now have a “market outperform” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $21.00 to $18.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $15.00 price target on the stock.

Evolent Health Trading Up 2.4 %

Shares of Evolent Health stock traded up $0.21 during trading on Wednesday, reaching $8.76. The company’s stock had a trading volume of 3,355,823 shares, compared to its average volume of 2,529,815. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -10.68 and a beta of 1.45. The firm’s 50-day moving average is $10.50 and its two-hundred day moving average is $18.01. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $34.84. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). The firm had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, sell-side analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Brendan B. Springstubb purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the completion of the acquisition, the director now directly owns 11,842 shares in the company, valued at approximately $103,617.50. The trade was a 73.08 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Evolent Health

Several institutional investors and hedge funds have recently modified their holdings of EVH. Cadian Capital Management LP purchased a new stake in Evolent Health in the fourth quarter worth about $58,781,000. Wellington Management Group LLP lifted its stake in shares of Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after purchasing an additional 1,426,747 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Evolent Health by 1,948.5% during the third quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock valued at $42,289,000 after purchasing an additional 1,422,385 shares in the last quarter. Engaged Capital LLC raised its holdings in Evolent Health by 35.5% in the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company’s stock worth $60,804,000 after purchasing an additional 1,415,300 shares in the last quarter. Finally, Boston Partners lifted its position in Evolent Health by 92.0% during the fourth quarter. Boston Partners now owns 2,444,006 shares of the technology company’s stock valued at $27,097,000 after buying an additional 1,171,304 shares during the period.

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.